Drug Trial Radar · NCT06771063
A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients
Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Jan 13, 2025
Primary completion
Jul 10, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Cisen Pharmaceutical CO., LTD.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, active-controlled, dose-ranging clinical trial designed to evaluate the efficacy and safety of the investigational drug compared to the active comparator in the treatment of vulvovaginal candidiasis. The trial consists of three phases: screening/enrollment (D-3 to D-1), treatment period (D1 to D3), and follow-up period (D4, D11±2, D25±3). Eligible subjects in this study will be randomized in a 1:1:1:1 ratio to three investigational drug arms with different dosing regimens and one active control arm. Specifically, Group A will receive WXSH0102 tablets with 1400 mg on the first day followed by a maintenance dose of 700 mg for two consecutive days, Group B will receive WXSH0102 tablets with 1000 mg on the first day followed by a maintenance dose of 500 mg for two consecutive days, Group C will receive WXSH0102 tablets with 600 mg on the first day followed by a maintenance dose of 300 mg for two consecutive days, and Group D (active control group) will receive fluconazole capsules for only one day on D1. All medications will be administered orally.
Conditions
- Vaginitis
Interventions
WXSH0102/placeboDrug
Administer WXSH0102 tablets/placebo orally.
fluconazole capsules/placeboDrug
Administer fluconazole capsules/placebo orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving cure at the D11±2 visit.Time frame: day 11±2
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
251 Yaojiayuan Road, Chaoyang District, Beijing
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Obstetrics and Gynecology Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.